Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2006

View Archived Issues

Zebularine improves survival in mouse model of T-cell lymphoma

LY-354740 prodrug, LY-544344, has greater behavioral effects in vivo

Glycyl-glutamine suppresses nicotine addiction in rats

N-Acetylcysteine well tolerated in cocaine-dependent individuals

OPT-80 shows efficacy in CDAD in phase IIa studies

Arimoclomol open-label extension study opens for ALS patients

NE-180 studied in phase I trial

OncoVEX(GM-CSF) studied for malignant melanoma, head and neck cancer

Advances in diagnostic tests for Alzheimer's disease

Acrux acquires rights to commercialize contraceptive spray

Novel Gb3 synthetic analogue demonstrates anti-HIV promise

Potent antimicrobial activity of a re-engineered vancomycin

Initiation of Veronate rolling BLA

AT-2101 receives orphan drug designation for Gaucher's disease

Novavax enters research collaboration with U. of Pittsburgh

Lilly and Boehringer Ingelheim amend Yentreve/AriClaim agreements

Phase I study of MEM-3454 completes dosing

sBLA filed for adjuvant Herceptin in early-stage HER2-positive breast cancer

Keryx inlicenses novel phosphate binder Zerenex

OSI begins phase I study with glucokinase activator PSN-010

Januvia NDA accepted for review

Accentia's IND for SinuNase on track

FDA lifts clinical hold on Tysabri in multiple sclerosis

Resistance profiling of a novel anti-V3 monoclonal antibody

ANA-380 achieves robust viral load reduction in lamivudine-resistant HBV patients

Novel agents reported for arthritis and other inflammatory disorders

Novel 5-HT2C receptor agonists emerge from Athersys R&D

Disruption of coordinated heart growth and angiogenesis contributes to heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...